New drug combo aims to knock out dangerous virus in transplant patients
NCT ID NCT06334497
Summary
This study is testing whether adding a new drug, letermovir, to the standard antiviral medication (valganciclovir) works better to treat cytomegalovirus (CMV) infections in people who have received a kidney transplant. The goal is to clear the virus from the blood faster and reduce the risk of the virus becoming resistant to treatment. The trial will involve 80 adult kidney transplant recipients in France who have an active CMV infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre 011-Hôpital Bichat, Service de Néphrologie
RECRUITINGParis, Île-de-France Region, 75018, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Européen Georges Pompidou
RECRUITINGParis, Île-de-France Region, 75015, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Necker Enfants Malades
RECRUITINGParis, 75015, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Necker Enfants Malades - SMIT
RECRUITINGParis, Île-de-France Region, 75015, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital de la Pitié Salpêtrière, Service de Néphrologie
RECRUITINGParis, Île-de-France Region, 75013, France
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.